Streetbeat News

Products Services

PYPD

PolyPid provides an update on its SHIELD II trial, which aims to address the rising rates of surgical site infections (SSIs) post-COVID. With 250 out of 600 patients enrolled, an unblinded interim analysis will be conducted after 400 patients complete their 30-day follow-up. Top-line results are expected in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:18 am

PM

Philip Morris International shares are trading lower after its subsidiary, Swedish Match North America, received a subpoena from the Attorney General of the District of Columbia and announced the suspension of online sales on ZYN.com.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:18 am

STLA

Stellantis NV (NYSE:STLA) is recalling over 1 million vehicles in the U.S. due to an issue with the rearview camera image display. The recall affects various models including Dodge Durango, Chrysler Pacifica, and Jeep Grand Cherokee L. Dealers will update the radio software free of charge.

Portfolio Pulse from Anan Ashraf

June 18, 2024 | 11:17 am

ZNTL

Zentalis Pharmaceuticals announced that the FDA has placed a partial clinical hold on ZN-c3-001, DENALI, and TETON monotherapy studies of Azenosertib following two recent deaths due to presumed sepsis in the DENALI study.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:16 am

IMCR

Immunocore has announced the randomization of the first patient in the PRISM-MEL-301 trial of Brenetafusp (IMC-F106C; PRAME-A02) in combination with Nivolumab for first-line advanced or metastatic cutaneous melanoma.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:13 am

DFLI

Dragonfly Energy has partnered with Meyer Distributing to expand the reach of its Battle Born Batteries into new markets. This strategic partnership aims to leverage Meyer Distributing's extensive distribution network to drive sales and market penetration for Dragonfly Energy's products.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:12 am

RGNX

Regenxbio has concluded a pre-biologics license application (BLA) meeting with the FDA for its RGX-121 treatment for Mucopolysaccharidosis Type II. The company plans to initiate a rolling BLA submission in Q3 2024, with a confirmatory trial expected to begin in H2 2025. The FDA has confirmed that the commercial bulk drug is comparable to the clinical material.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:11 am

CLNN

Clene presented new long-term results for its CNM-Au8 treatment at the European Network for the Cure of ALS meeting, showing improved survival and reduced neurofilament light levels in ALS patients.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:09 am

IONS

Otsuka Pharmaceutical has obtained exclusive rights across the Asia-Pacific region for Ionis Pharmaceuticals' donidalorsen for hereditary angioedema. Ionis will receive a $20M upfront payment and milestone payments. Ionis will handle primary development, while Otsuka will manage territory-specific development, regulatory filings, and commercialization in the Asia-Pacific region and Europe.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:06 am

LQDT

Liquidity Services has partnered with Aaron Industrial Solutions and Binswanger to sell a turnkey medical device manufacturing plant. This collaboration aims to leverage the expertise of all three companies to maximize the value of the sale.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 10:51 am